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Background: Cisplatin, a platinum-derived chemotherapeutic agent, produces antineoplastic effects coupled with
toxic neuropathic pain and impaired general health status. These side-effects complicate long term studies of
neuropathy or analgesic interventions in animals. We recently demonstrated that pretreatment with sodium bicarbonate
(4% NaHCO3) prior to cisplatin (3 mg/kg i.p. weekly up to 5 weeks) was associated with improved health status (i.e. normal
weight gain, body temperature, creatinine and ketone levels, and kidney weight ratio) in rats (Neurosci Lett 544:41-46,
2013). To reduce the nephrotoxic effects of cisplatin treatment in mice, we compared effects of sodium bicarbonate (4%
NaHCO3 s.c.), vitamin C (25 mg/kg s.c.), resveratrol (25 mg/kg s.c.) and saline (0.9% NaCl) pretreatment on cisplatin-induced
changes in animal health status, neuropathic pain and proinflammatory cytokine levels in spinal cord and kidney.
Results: Cisplatin-treated mice receiving saline pretreatment exhibited elevated ketone, creatinine and kidney weight
ratios, representative of nephrotoxicity. Vitamin C and sodium bicarbonate lowered creatinine/ketone levels and kidney
weight ratio whereas resveratrol normalized creatinine levels and kidney weight ratios similar to saline pretreatment. All
pretreatments were associated with decreased ketone levels compared to saline pretreatment. Cisplatin-induced
neuropathy (i.e. mechanical and cold allodynia) developed equivalently in all pretreatment groups and was similarly
reversed by either morphine (6 mg/kg i.p.) or ibuprofen (6 mg/kg i.p.) treatment. RT-PCR showed that mRNA levels for
IL-1β were increased in lumbar spinal cord of cisplatin-treated groups pretreated with either saline, NaHCO3 or resveratrol/
cisplatin-treated groups. However, IL-6 and TNF-alpha were elevated in the kidneys in all cisplatin-treated groups. Our
studies also demonstrate that 60 days after the last cisplatin treatment, body weight, body temperature, kidney functions
and mRNA levels have returned to baseline although the neuropathic pain (mechanical and cold) is maintained.
Conclusions: Studies employing cisplatin should include NaHCO3 or vitamin C pretreatment to improve animal health
status and reduce nephrotoxicity (lower creatinine and kidney weight ratio) without affecting the development of
chemotherapy-induced neuropathy or analgesic efficacy.
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Neck cancer patients receive cycles of the platinum-
derived chemotherapeutic agent cisplatin once every
four weeks over an extended and defined period of time
[1,2]. However, preclinical studies typically administer
high doses of cisplatin either acutely or over restricted
intervals in the context of restricted survival times
[3,4]. The failure of preclinical studies to more closely
represent the clinical dosing schedule likely reflects
the fact that cisplatin treatment is associated with
known toxicities that impair general health status. These
toxicities render long term evaluations of therapeutic
efficacy and even animal survival problematic. Only a
few preclinical studies have used these paradigms
[5-10]. Specifically, renal toxicity [11-13] critically im-
pairs animal health and undermines long term studies
aimed at identifying mechanisms of cisplatin-induced
neuropathies or effective treatments. Indeed, cisplatin
produces painful as well as nonpainful sensory neuropa-
thies through mechanisms that remain poorly understood.
Cisplatin-induced nephrotoxic effects impair animal health
and impede investigations aimed at understanding the
resulting neuropathies and long term treatments [14-17].
Attempts to buffer acidic effects of cisplatin to minimize
renal toxicity with alkaline pretreatments show beneficial
effects in preclinical [8] and clinical [18] studies. Ma-
nipulating diets of cancer patients toward alkaline pH
attenuates cancer cell survival and reduces renal toxicity, a
dose-limiting consequence of repeated cisplatin treatment
[18,19]. Human studies have demonstrated the beneficial
effects of sodium bicarbonate in reducing blood acidosis
and kidney toxicity in chemotherapy patients [18,19]. Re-
cently, we established a rat model of cisplatin-induced
neuropathy in which pretreatment with sodium bicarbonate
(4% NaHCO3 administered subcutaneously (s.c.)) prior to
once weekly cisplatin dosing over 16 or 28 days minimized
damage to renal functions (creatinine levels, kidney weight
ratio and pH of urine). This pretreatment was associated
with improved general health status (normal weight gain,
normal body temperature and no mortality) that should
permit long term evaluations in preclinical studies [8].
Thus, alkaline solutions can be used to counteract acidic
effects of cisplatin that cause nephrotoxicity and mortality
in rats. However, antioxidants such as vitamin C and
resveratrol also confer protective effects against cisplatin-
induced nephrotoxicity without negativetly affecting its
bioavailability in rodents [13,20-23]. This antioxidant
effect is mediated by reducing oxidative stress which is
protective against various injuries [21]. Moreover, vitamin
C also attenuates the lipid peroxidation glutathione deple-
tion and decreases in glomerular filtration rate that are
induced by cisplatin treatment [21,22]. Extension of these
renal protective effects of alkaline diet/solution or an-
tioxidants (vitamin C, resveratrol) to a mouse model ofcisplatin-induced neuropathy is critical if we are to
fully exploit the power of transgenic approaches for
identifying and validating therapeutic targets for treat-
ing and preventing neuropathy in humans. The present
study was designed to develop an improved mouse
model of cisplatin-induced neuropathy by comparing
different pretreatments (saline, sodium bicarbonate,
vitamin C, or resveratrol) aimed at minimizing detrimen-
tal effects of cisplatin on body weight, body temperature,
and kidney functions (creatinine levels, kidney weight ra-
tio and urinary pH). We also evaluated transcriptional
regulation of pro-inflammatory cytokines (IL-1β, IL-6,
IL-10 and TNFα) in kidney and lumbar spinal cord fol-
lowing each treatment. These studies used a repeated
cisplatin dosing paradigm to better mimic the clinical
condition. We also investigated the impact of different
pretreatments (i.e. saline, sodium bicarbonate, vitamin
C or resveratrol) on cisplatin-induced mechanical and
cold allodynia and compared the antinociceptive efficacy
of reference analgesics (i.e. an opioid (morphine) and a
nonsteroidal anti-inflammatory drug (ibuprofen)) since
these compounds are widely use in cancer patients
treated with chemotherapeutic agents [1,2,11,12]. Finally,
we evaluated the long term effects (60 days following
cessation of repeated cisplatin dosing) of saline, saline/
cisplatin and vitamin C/cisplatin-treated mice on animal
health status (i.e. body weight, body temperature), kidney
functions (creatinine, kidney weight ratios), neuropathic
pain (mechanical and cold allodynia) as well mRNA levels
of inflammatory cytokines (IL-1β, IL-6, IL-10 and TNFα)
in both lumbar spinal cord and kidney.
Results
Cisplatin-untreated control groups
No differences were observed between any of the pre-
treatment groups in animals that received saline vehicle in
lieu of cisplatin in body weight (F3,14 = 0.42, P = 0.739),
body temperature (F3,14 = 1.30, P = 0.312), mechanical
threshold (F3,14 = 1.03, P = 0.408) or latency to respond to
cold stimulation (F3,14 = 2.20, P = 0.133). Similarly, no dif-
ferences in blood creatinine (F3,8 = 0.50, P = 0.691), ketone
(F3,8 = 2.62, P = 0.123), glucose (F3,8 = 0.07, P = 0.973) or
kidney weight ratios (F3,8 = 0.67, P = 0.594) were observed
in any pretreatment group not receiving cisplatin. Similarly,
urine pH (F3,8 = 0.32, P = 0.813) and blood pH (F3,8 = 1.04,
P = 0.425) were similar in saline/saline or pretreated
(vitamin C, resveratrol or NaHCO3)/saline groups. Con-
sequently, these groups were pooled into a single control
group (the control/saline group) for each survival time for
further statistical analysis.
Body weight
Body weight did not differ between any pretreatment
(saline, NaHCO3, vitamin C, resveratrol) groups over
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vation day; Figure 1A). By contrast, the control/saline
group exhibited time-dependent increases in body
weight (F36,486 = 11.51, P < 0.0001; Figure 1A) from day
12 to day 36 (P < 0.0001 for all time points). Body weight
was higher in control/saline compared to all cisplatin
groups receiving different pre-treatments (F4,54 = 18.90,
P < 0.0001). Indeed, weight gain in the control/saline group
appeared on day 12 and persisted to day 36 (P < 0.042)
(Figure 1A). There were no differences in body weight in
the different pre-treatment/cisplatin groups from day 12
to day 32 (P > 0.067). However, on day 36, reseveratrol
pretreatment was associated with decreased body weight
in comparison to vitamin C pretreatment (P < 0.048).
Body temperature
Body temperature did not differ in control/saline mice
or in the different cisplatin pretreatment groups (saline,
NaHCO3, vitamin C, resveratrol)/cisplatin-treated mice)
from day 0 (Baseline) through day 16 (P ≥ 0.153 for eachFigure 1 Impact of cisplatin on body weight, body temperature, mec
treatments (NaHCO3, vitamin C, resveratrol) or saline. (A) Body weight
saline in lieu of cisplatin with different (saline, NaHCO3, vitamin C, resveratr
(A) Body weight and (B) body temperature was lowest in cisplatin-treated
attenuated cisplatin-induced decreases in body temperature. Time course of
groups pretreated with saline, NaHCO3, vitamin C or resveratrol. Mechanical a
of cisplatin with different (saline, NaHCO3, vitamin C, resveratrol) pretreatment
timing of injections of chemotherapeutic agents. Data are expressed as mean
or resveratrol/cisplatin-treated groups vs. control saline group (ANOVA, Bonfe
(ANOVA, Bonferroni post hoc); # P < 0.0001 for saline or resveratrol/cisplatin-tr
^ P < 0.007 for vitamin C or NaHCO3/cisplatin groups vs. saline/cisplatin groupobservation day; Figure 1B). However, both saline and
resveratrol/cisplatin-treated groups exhibited lower body
temperature relative to the control/saline group; lower
body temperature was observed starting on day 20 and was
maintained throughout the study (F4,54 = 23.75, P < 0.0001;
days 20–36 (P < 0.002); Figure 1B). Body temperature did
not differ in the saline/cisplatin group from that observed
in the resveratrol/cisplatin group (P = 0.237) at any ob-
servation interval. Body temperature was lower in the
saline/cisplatin groups compared to either vitamin C
or NaHCO3/cisplatin-treatment, on day 24, 28 and 36
(P ≤ 0.007, P ≤ 0.0001 and P ≤ 0.0001 for each observation
day, respectively). On those days, body temperature did
not differ in either vitamin C/cisplatin or NaHCO3/cis-
platin groups (P = 1.000).
Cisplatin-induced mechanical and cold allodynia
Cisplatin lowered paw withdrawal thresholds in all pre-
treatment groups (i.e. saline, NaHCO3, vitamin C, resvera-
trol)/cisplatin-treated groups) relative to the control/salinehanical and cold allodynia in groups pretreated with antioxidant
and (B) body temperature did not differ between groups receiving
ol) pretreatments and were pooled into a single control/saline group.
rats receiving saline or resveratrol pretreatment. Vitamin C and NaHCO3
development of (C) mechanical and (D) cold allodynia in cisplatin-treated
nd cold sensitivity did not differ between groups receiving saline in lieu
s and were pooled into a single control/saline group. Arrows show
± s.e.m. (n = 9–18 per group). *P < 0.0001 for saline, NaHCO3, vitamin C
rroni post hoc); + P < 0.048 for vitamin C vs. resveratrol/cisplatin group
eated groups vs. control saline group (ANOVA, Bonferroni post hoc);
(ANOVA, Bonferroni post hoc).
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with the development of mechanical allodynia. Mech-
anical allodynia was present from day 4 to day 36
(P < 0.0001) (Figure 1C) post initial cisplatin dosing. Fur-
thermore, all cisplatin-treated groups showed similar
increases in the latency of paw withdrawal to acetone
in comparison to control/saline group (F4,54 = 6161.90,
P < 0.0001) (Figure 1D), consistent with development
of cold allodynia. Cold allodynia was similarly present
from day 4 to day 36 (P < 0.0001) (Figure 1D) post initial
cisplatin dosing.Figure 2 Morphine and ibuprofen suppress cisplatin-induced mech
pretreated with saline, vitamin C, NaHCO3 or resveratarol. Mechanical
groups receiving different pretreatments (saline, NaHCO3, vitamin C, or r
pooled into a single pooled/cisplatin-vehicle group. On day 36, morphin
time-dependent suppressions of cisplatin-induced mechanical (B, C) an
group). *P < 0.0001 for all different (saline, vitamin C, resveratrol or NaHC
(ANOVA, Bonferroni post hoc).Comparison of antinociceptive efficacy of morphine and
ibuprofen in cisplatin-treated mice receiving different
pretreatments
There were no differences in mechanical (F3,16 = 0.33,
P = 0.799; at all observation intervals P > 0.669; Figure 2A)
or cold (F3,16 = 2.39, P = 0.107; at any time points
P > 0.258; Figure 2D) allodynia in cisplatin-treated groups
receiving vehicle that also received saline, vitamin C,
resveratrol or NaHCO3 pretreatments. Therefore, these
groups were pooled together into a single cisplatin-
vehicle group for further statistical analyses.anical and cold allodynia with equivalent efficacy in mice
(A) and cold (D) sensitivity did not differ between cisplatin-treated
esveratrol) that subsequently received vehicle; these groups were
e (6 mg/kg i.p.) (B, E) and ibuprofen (6 mg/kg i.p.) (C, F) produced
d cold (E, F) allodynia. Data are expressed as mean ± s.e.m. (n = 5 per
O3) pretreated/cisplatin groups vs. control/cisplatin-vehicle group
Figure 3 Kidney functions assessment in saline or cisplatin-treated
groups receiving different pretreatments (saline, NaHCO3, vitamin
C, or resveratrol). (A) Creatinine levels were increased in saline/cisplatin
and resveratrol/cisplatin groups relative to control/saline treatment.
Both vitamin C and NaHCO3 pretreatments blocked cisplatin-induced
increases in creatinine levels. (B) Ketone levels are increased in saline/
cisplatin group but not in control/saline, vitamin C, NaHCO3 or resveratrol/
cisplatin-treated groups. (C) Glucose levels and (D) blood pH did not
differ between control/saline or any cisplatin-treated group. (E) Urine
pH was elevated in the NaHCO3/cisplatin group in comparison to
control/saline, saline/cisplatin or vitamin C/cisplatin groups. (F) Kidney
weight ratios are increased in saline/cisplatin and resveratrol/cisplatin
groups relative to control/saline, vitamin C or NaHCO3 treated groups.
Data are expressed as mean ± s.e.m. (n = 8 per group). *P < 0.001 vs.
control/saline, vitamin C or NaHCO3/cisplatin groups (ANOVA, Bonferroni
post hoc); + P < 0.0001 vs. control/saline, vitamin C, NaHCO3 or
resveratrol/cisplatin-treated groups (ANOVA, Bonferroni post hoc);
# P < 0.0001 vs. control saline, saline/cisplatin or vitamin C/cisplatin
groups (ANOVA, Bonferroni post hoc).
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anical (F4,35 = 44.33, P < 0.0001; Figure 2B) and cold (F4,35 =
849.36, P < 0.0001; Figure 3E) allodynia in all pretreatment
(saline, NaHCO3, vitamin C, resveratrol; P < 0.0001 for
each) groups relative to vehicle treatment. Morphine also
produced time-dependent attenuations of mechanical
(F20,175 = 25.76, P < 0.0001) (Figure 2B) and cold (F20,175 =
368.29, P < 0.0001) (Figure 2E) allodynia relative to pre-
injection baseline thresholds. Anti-allodynic effects of
morphine on mechanical and cold sensitivity were
observed relative to vehicle at 30 (P < 0.0001) and
90 min (P < 0.0001) post-injection for each pretreatment
(Figure 2B and E, respectively).
Similarly, ibuprofen (6 mg/kg) suppressed cisplatin-
induced mechanical (F4,35 = 34.21, P < 0.0001; P < 0.0001;
Figure 2C) and cold (F4,35 = 445.09, P < 0.0001; Figure 2 F)
allodynia in all pretreatment (saline, NaHCO3, vitamin C,
resveratrol) groups relative to cisplatin-vehicle treatment
(P < 0.0001 for each pretreatment). Ibuprofen produced a
time-dependent attenuation of mechanical (F20,175 = 22.80,
P < 0.0001; Figure 2C) and cold (F20,175 = 253.99, P < 0.0001;
Figure 2 F) allodynia relative to pre-injection baseline
thresholds. Anti-allodynic effects of ibuprofen on mechan-
ical and cold sensitivity were observed, relative to vehicle
treatment, at 30 (P < 0.0001) and 90 min (P < 0.0001) post-
injection in each pretreatment group (Figure 2C and F).
Kidney functions
Both saline/cisplatin and resveratrol/cisplatin-treated
groups exhibited similar (P = 1.000) increases in creatinine
(F4,39 = 8.59, P < 0.0001) (Figure 3A) levels in whole blood
relative to control/saline, vitamin C or NaHCO3/cisplatin-
treated groups. Moreover, vitamin C and NaHCO3/
cisplatin groups showed creatinine levels that are similar
to those observed in control/saline groups (P = 1.000).
Saline/cisplatin-treated groups also showed elevated
ketone levels relative to all other treatments (F4,39 = 10.54,
P < 0.0001) (Figure 3B). Blood glucose levels (F4,39 = 0.25,
P = 0.906) did not differ between control/saline and any
cisplatin-treated groups (Figure 3C).
No changes were observed in blood pH (F4,39 = 0.37,
P = 0.829, 36 days) (Figure 3D) in any group. NaHCO3/
cisplatin treatment (F4,39 = 9.57, P < 0.0001) (Figure 3E)
increased urinary pH in comparison to control/saline,
saline/cisplatin or vitamin C/cisplatin-treated groups
(Figure 3E). There was no difference in the urinary pH
of these latter groups (control saline, saline/cisplatin
or vitamin C/cisplatin) (P > 0.158). NaHCO3/cisplatin
increased urinary pH to a level comparable to resveratrol
pretreatment (P > 0.149) (Figure 3E). Resveratrol/cisplatin
and saline/cisplatin groups also exhibited elevated kidney
weight ratios (F4,39 = 24.99, P < 0.0001) 36 days post initial
cisplatin dosing relative to either control/saline, vitamin
C or NaHCO3/cisplatin-treated groups (Figure 3 F). The
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platin and NaHCO3/cisplatin-treated mice were similar
(P = 1.000), suggesting that both vitamin C and NaHCO3
pretreatment prevented cisplatin-induced increases in kid-
ney weight ratios.
One out of 11 mice (9.09%) died (on day 20) in the
saline/cisplatin group that precluded further cisplatin
dosing. By contrast, mortality was absent in cisplatin-
treated groups pretreated with vitamin C, NaHCO3 or
resveratrol (n = 9–11 per group).Figure 4 mRNA levels of inflammatory cytokines (IL-1β, IL-6,
IL-10 and TNFα) in lumbar spinal cord and kidneys. IL-1β (A)
mRNA levels are increased in lumbar spinal cord of saline, NaHCO3
or resveratrol/cisplatin-treated groups relative to the control/saline
or vitamin C/cisplatin groups. Resveratrol/cisplatin group exhibited
higher IL-1β mRNA levels relative to vitamin C/cisplatin group (A).
IL-6, TNFα and IL-10 spinal cord mRNA levels did not differ reliably
between groups. (B) In the kidneys, levels of IL-6 and TNFα mRNAsmRNA Quantification of IL-1β, IL-6, IL-10 and TNFα in
lumbar spinal cord and kidneys
RT-PCR analysis revealed that IL-1β mRNA levels were
increased in the lumbar spinal cord of saline, NaHCO3 and
resveratrol/cisplatin-treated groups (F4,15 = 3.27, P < 0.041)
relative to control/saline or vitamin C/cisplatin groups
(Figure 4A). Indeed, control/saline and vitamin C/cisplatin
groups showed similar IL-1β mRNA levels in spinal cord
(P = 1.000). The resveratrol/cisplatin group exhibited
increased IL-1β mRNA levels relative to vitamin C/cis-
platin (P < 0.046) group. By contrast, mRNA levels of IL-6
(P = 0.101), TNFα (P = 0.177) and IL-10 (P = 0.307) did
not differ reliably between groups in the spinal cord
(Figure 4A).
In the kidneys, cisplatin-treated mice exhibit higher
mRNA levels of IL-6 (F4,13 = 3.81, P < 0.029) and TNFα
(F4,13 = 3.29, P < 0.045) in comparison to the control/saline
group (Figure 4B). Moreover, resveratrol/cisplatin group
exhibited increased IL-6 (P < 0.03) and TNFα (P < 0.043)
mRNA levels relative to the control/saline group
(Figure 4B). mRNA levels of IL-1β (P = 0.415) and
IL-10 (P = 0.153) in the kidneys did not differ reliably be-
tween groups (Figure 4B).were higher in cisplatin-treated mice compared to the control/saline
group. Resveratrol/cisplatin group shows higher IL-6 and TNFα
mRNA levels relative to control/saline group. IL-1β and IL-10 mRNA
levels in the kidneys did not differ reliably between groups (B). Data
are expressed as mean ± s.e.m. (n = 4 per group). *P < 0.041 vs.
control/saline or vitamin C/cisplatin (ANOVA, Bonferroni post hoc); +
P < 0.046 for resveratrol/cisplatin group vs. vitamin C/cisplatin-treated
group (ANOVA, Bonferroni post hoc); ^ P< 0.045 vs. control/saline group
(ANOVA, Bonferroni post hoc); # P < 0.043 for resveratrol/cisplatin
group vs. control saline group (ANOVA, Bonferroni post hoc).Long term effects of vitamin C pretreatment on body
weight in cisplatin-treated mice
Body weight gain did not differ in control/saline-treated
mice in comparison to saline/cisplatin or vitamin C/
cisplatin treatments from day 0 (Baseline) through day
8 (P ≥ 0.449 for each timepoint) or from day 56 to the
end of the study (P ≥ 0.203 for each timepoint). By
contrast, the control/saline group exhibited time-dependent
increases in body weight (F48,432 = 5.78 P < 0.0001;
Figure 5A) from day 12 to day 52 (P < 0.013 for all
time points). Body weight was higher in control/saline
compared to saline/cisplatin or vitamin C/cisplatin-treated
groups (F2,18 = 4.27, P < 0.030). Indeed, weight gain in the
control/saline group appeared on day 12 (P < 0.002) and
persisted through day 52 (P < 0.002) (Figure 5A). Body
weight did not differ between saline/cisplatin and vitamin
C/cisplatin groups from day 12 to day 52 (P > 0.162) with
one exception (i.e. day 36). Indeed, on day 36, body weightwas lower in the saline/cisplatin group in comparison to
vitamin C/cisplatin treatment (P < 0.018).
Long term effects of vitamin C pretreatment on body
temperature in cisplatin-treated mice
Body temperature did not differ in control/saline mice
relative to other pretreatments (saline or vitamin C)/cis-
platin in mice from day 0 (Baseline) (P = 0.211) to day 20
(P = 0.129) or from day 44 (P = 0.961) to day 96 (P = 0.861)
(Figure 5B). However, body temperature was lower in the
Figure 5 Long term effects of cisplatin on body weight, body temperature, mechanical and cold allodynia in control/saline, saline/cisplatin
or vitamin C/cisplatin groups. Weight gain (A) is decreased in cisplatin-treated mice from day 12 to day 52 relative to control saline group. On day
36, saline/cisplatin exhibit lower body temperature than vitamin C/cisplatin group. Weight gain is similar in saline or cisplatin-treated groups from day
56 to 96. Body temperature (B) did not differ in the control/saline group relative to vitamin C/cisplatin group at any observation interval (from day 0 to
day 96). Indeed,vitamin C pretreatment blunted cisplatin-induced decreases in body temperature. Time course of development of mechanical (C) and
cold (D) allodynia in cisplatin-treated groups pretreated with saline or vitamin C. Arrows show timing of injections of chemotherapeutic agents. Data
are expressed as mean ± s.e.m. (n = 6–8 per group). *P < 0.03 vs. control/saline group (ANOVA, Bonferroni post hoc); + P < 0.018 for vitamin C/cisplatin
vs. saline/cisplatin group (ANOVA, Bonferroni post hoc); # P < 0.041 vs. control/saline or vitamin C/cisplatin-treated groups (ANOVA, Bonferroni
post hoc).
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min C/ cisplatin groups from day 24 to day 40 (F2,18 = 5.04,
P < 0.018; P < 0.041 for each time point; Figure 5B). Body
temperature did not differ in the control/saline group
relative to vitamin C/cisplatin group (P > 0.109) at any
observation interval (from day 0 to day 96).
Long term effects of vitamin C pretreatment on
cisplatin-induced mechanical and cold allodynia
Both saline/cisplatin and vitamin C/cisplatin-treated
groups exhibited lowered paw withdrawal thresholds
relative to control/saline group (F2,18 = 3418.38, P < 0.0001)
(Figure 5C), consistent with the cisplatin-induced develop-
ment of mechanical allodynia. Mechanical allodynia was
present from day 4 to day 96 (P < 0.0001) (Figure 5C) post
initial cisplatin dosing. Furthermore, all cisplatin-treated
groups showed similar increases in the duration of
responding to acetone in comparison to control/saline
group (F2,18 = 56173.62, P < 0.0001) (Figure 5D), consist-
ent with development of cold allodynia. Cold allodynia
was similarly present from day 4 to day 96 (P < 0.0001)
(Figure 5D) post initial cisplatin dosing.Long term effects of vitamin C pretreatment on kidney
functions in cisplatin-treated mice
Creatinine (F2,18 = 2.63, P = 0.10), ketone (F2,18 = 0.55,
P = 0.585) and glucose (F2,18 = 0.12, P = 0.884) levels
were similar in control/saline, saline/cisplatin and vitamin
C/cisplatin groups that received their last cisplatin treat-
ment 60 days ago (Figure 6A-C). Furthermore, urine pH
(F2,18 = 2.82, P = 0.086), blood pH (F2,18 = 0.236, P = 0.792)
and kidney weight ratio (F2,18 = 0.32, P = 0.267) did not
differ between control/saline, saline/cisplatin or vitamin
C/cisplatin groups at this time point (Figure 6D-F). Thus,
detrimental effects of cisplatin on kidney functions were
no longer present 60 days following termination of cis-
platin dosing in any group.
Long term effects of vitamin C pretreatment on mRNA
levels of cytokines (IL-1β, IL-6, IL-10 and TNFα) in the
spinal cord and kidneys following cisplatin treatment
Cisplatin mice pretreated with vitamin C exhibited modest
decreases (F2,9 = 5.802, P < 0.024) in IL-1β mRNA in the
lumbar spinal cord (Figure 7A) 60 days after the last cycle
of cisplatin. IL-1β mRNA levels were higher in the
Figure 6 Long term assessment of kidney functions in control/
saline, saline/cisplatin or vitamin C/cisplatin groups. Creatinine
(A), ketone (B) and glucose (C) levels as well as blood pH (D), urine
pH (E) and kidney weight ratios (F) were similar in control/saline,
saline/cisplatin or vitamin C/cisplatin groups 60 days after the last
cisplatin injection. Data are expressed as mean ± s.e.m. (n = 6–8
per group).
Figure 7 Long term effects on mRNA levels of inflammatory
cytokines (IL-1β, IL-6, IL-10 and TNFα) in the lumbar spinal cord
and kidneys. IL-1β mRNA levels are decreased in vitamin C/cisplatin
treated group relative to control/saline group in the lumbar spinal
cord (A). IL-1β mRNA levels in spinal cord were similar in control/
saline and saline/cisplatin groups. IL-6, TNFα or IL-10 mRNA levels
were not altered in the spinal cord of control/saline, saline/cisplatin
or vitamin C/cisplatin groups (A). No changes were observed in mRNA
levels of TNFα, IL-6, IL-1β and IL-10 in the kidneys (B) of control/saline,
saline/cisplatin or vitamin C/cisplatin groups. Tissue was harvested
60 days following the last cisplatin dose. Data are expressed as mean
± s.e.m. (n = 4 per group). *P < 0.024 vs. control/saline group (ANOVA,
Bonferroni post hoc).
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group (P < 0.028) (Figure 7A). IL-1β mRNA levels in the
spinal cord were similar (P = 0.121) in control/saline and
saline/cisplatin groups. No changes in IL-6 (P = 0.750),
TNFα (P = 0.439) or IL-10 (P = 0.766) mRNA levels were
observed in any group 60 days after the last cisplatin ad-
ministration (Figure 7A).
No changes in mRNA levels of IL-6 (P = 0.749), TNFα
(P = 0.750), IL-1β (P = 0.553) and IL-10 (P = 0.803) were
detected in the kidneys (Figure 7B) of control/saline,saline/cisplatin or vitamin C/cisplatin groups at this time
point.
Discussion
Cisplatin produces nephrotoxicity that becomes more
severe following repeated dosing and can result in mortal-
ity [6,24]. Antioxidants (vitamin C and E, resveratrol, sel-
enium, cysteine, quercetin) have been shown to protect
against cisplatin-induced nephrotoxicity [20-23]. This
effect is mediated by reducing oxidative stress which is
protective against various injuries [21]. Vitamin C also at-
tenuates the decrease in glomerular filtration rate that is
induced by cisplatin treatment [21,22]. Vitamin C and E
also have hepatoprotective effects [25,26]. Thus, sodium
bicarbonate, resveratrol as well as vitamin C may exert
protective effects on the kidney functions [8,20,25].
In the present study, we compared the effects of three
different potentially beneficial pretreatments — sodium
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and resveratrol (25 mg/kg s.c.) — with saline (0.9% NaCl))
on cisplatin-induced kidney function, mRNA expression
levels of pro-inflammatory cytokines, neuropathic allody-
nia and general health status. Our study demonstrates that
cisplatin-treated mice receiving saline pretreatment
exhibited elevated ketone, creatinine and kidney weight
ratios, representative of nephrotoxicity. Vitamin C and
sodium bicarbonate pretreatments lowered creatinine/
ketone levels and restored kidney weight ratio whereas
resveratrol pretreatment exhibited detrimental increases
in both creatinine levels and kidney weight ratio that
were similar to saline pretreatment. Thus, resveratrol
pretreatment was inferior to either vitamin C or sodium bi-
carbonate for protecting against cisplatin-induced nephro-
toxicity. However, all pretreatments decreased ketone levels
compared to saline pretreatment. In our previous work
in rats, pretreatment with 4% sodium bicarbonate
(NaHCO3) in lieu of 0.9% saline (s.c.) prior to cisplatin
dosing (3 mg/kg i.p. weekly up to 5 weeks) also showed
beneficial effects on both kidney functions and general
health status[8].
Weight loss was observed in all cisplatin-treated
groups beginning on day 12, but was most pronounced in
the resveratrol-pretreated group. The decrease in body-
weight was cisplatin-dependent because it was observed
after the third and fourth cycles of cisplatin dosing.
Interestingly, vitamin C-pretreated mice receiving cis-
platin exhibited increases in body weight compared to
the resveratrol-pretreated group, suggesting antioxidant
superiority of vitamin C. In a long term study, vitamin C
pretreatment was associated with increased body weight
relative to saline/cisplatin treatment that normalized to
control/saline animals by 56 days following initial cisplatin
dosing.
Resveratrol and saline/cisplatin-treated mice also ex-
hibited lowered body temperature (between days 20 to
day 36) indicative of impaired health status. Only sodium
bicarbonate and vitamin C pretreatments attenuated
cisplatin-induced decreases in body temperature. By
day 44 following initiation of cisplatin dosing (i.e. 9 days
following cessation of cisplatin administration), cisplatin
induced reductions in body temperature were no longer
observed. Although cisplatin lowered body temperature,
the values remain between 36 °C and 37 °C, so hypothermia
(below 35 °C) was not observed in any condition [27].
Mice receiving cisplatin in the absence of anti-oxidant
pretreatment could nonetheless be more susceptible to
hypothermic effects of various pharmacological inter-
ventions [24].
However, none of the anti-oxidant pretreatments used
altered the development or maintenance of neuropathic
allodynia in our cisplatin dosing paradigm. Development
of neuropathy was similar in the different pretreatment(sodium bicarbonate, vitamin C, resveratrol, or saline)
groups receiving the same doses of cisplatin. These
observations are consistent with the fact that mRNA
expression levels of pro-inflammatory cytokines, though
blunted by antioxidant treatment in kidney, remained ele-
vated in lumbar spinal cord. Cisplatin-induced mechanical
and cold allodynia was similarly preserved following
pretreatment with sodium bicarbonate in rats [8,28].
Moreover, mechanical and cold allodynia is maintained
for at least 60 days following the last cisplatin treatment.
Furthermore, morphine (6 mg/kg i.p.) and ibuprofen
(6 mg/kg i.p.) both reversed mechanical and cold allodynia
equivalently in all the pretreatment groups. To our know-
ledge, this is the first report of an anti-allodynic effect of
ibuprofen in the cisplatin model. The impact of ibuprofen
in altering the therapeutic activity of chemotherapeutic
agents or radiation treatment has been previously evalu-
ated [29-31] and shown to increase cellular sensitivity to
radiation [30].
We further evaluated the ability of different antioxidant
pretreatments to reduce the nephrotoxic effects of cisplatin,
as documented by cisplatin-induced increases in creatinine
levels, kidney weight ratio [8,27,32] and decreases in urin-
ary pH [8,19]. Indeed, resveratrol pretreatement failed to
protect against several signs of nephrotoxicity in our study
because cisplatin-induced increase in creatinine levels and
kidney weight ratio were observed following resveratrol
pretreatment in our study. Reports of resveratrol-induced
protection against nephrotoxicity using a shorter duration
of cisplatin (single administration of both cisplatin
5 mg/kg i.p. and resveratrol 25 mg/kg i.p. with survival
time of 2 or 5 days post injection vs. 36 days in our
study) treatment have been demonstrated [20]. Thus,
beneficial effects of resveratrol may only be observed
when cisplatin is administered acutely and short survival
times are employed. Consequently, such beneficial effects
may not translate to reductions in nephrotoxicity in the
clinical situation where longer durations of cisplatin ex-
posure are encountered. By contrast, cisplatin-treated
groups receiving either vitamin C or sodium bicarbon-
ate pretreatments exhibited lower creatinine levels and
kidney weight ratios that did not differ from the control/
saline group. Interestingly, only the sodium bicarbonate
pretreatment showed elevated urinary pH (normal urine
pH around 7.00) relative to the vitamin C or saline pre-
treated/cisplatin groups. This finding confirms results of
previous studies in patients [19] and rats [8]. Indeed, an
alkali pH (remain above 7.5) was observed in all (n = 26)
patients pre-treated with 8.4% sodium bicarbonate before
methotrexate treatment [19]. Resveratrol-treatment was
associated with a urinary pH that is similar to sodium
bicarbonate pretreatment, likely due to antioxidants
properties [20]. All pretreatments failed to alter blood pH,
as observed previously following sodium bicarbonate
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term evaluations of cisplatin treatment, creatinine, kidney
weight ratio, urine and blood pH were all normalized
to control levels in the different pretreatment groups
(control/saline, saline or vitamin C/cisplatin) measured
60 days after the last cisplatin injection.
We also evaluated the impact of our pretreatments on
fatty acid metabolism by measuring levels of ketone in
whole blood. Ketone is an end product of fatty acid
metabolism and high ketone levels are indicative of
keto-acidosis, a serious medical condition characterized
by high acidity of bodily fluids [27,33,34]. Cisplatin in-
creased ketone levels in saline pretreated groups in the ab-
sence of antioxidant treatment (Figure 3B) although
normal (7.37 ± 0.04) blood pH (normal blood pH between
7.35-7.45) [27] was observed. Thus, all pretreatments ef-
fectively blunted the cisplatin-induced increase in ketone
levels. However, cisplatin-induced elevations in ketone
levels were normalized by 60 days following cessation of
cisplatin dosing. Glucose levels (50–135 mg/dl) did not
differ amongst any of the saline or cisplatin treated
groups. Thus, our induction of neuropathy in our cisplatin
dosing paradigm cannot be associated with high levels of
glucose found in models of diabetic neuropathy [35].
In the spinal cord, cisplatin produced long term eleva-
tion in mRNA levels of the cytokine IL-1β in the saline,
NaHCO3 or resveratrol/cisplatin-treated groups, with
resveratrol/cisplatin showing higher IL-1β mRNA levels
relative to vitamin C/cisplatin group. The observed increase
in IL-1β mRNA is consistent with increases in IL-1β
protein following acute treatment with high dose
(30 mg/kg i.p.) of cisplatin [36] or in in vitro studies
using different cell lines [37,38]. IL-1β has been colo-
calized to astroglia but not neurons or microglia [39].
At 60 days post cisplatin, IL-1β mRNA levels are de-
creased in the vitamin C/cisplatin group in comparison
to the control/saline group whereas no changes are ob-
served in IL-6, TNF-α and IL-10 mRNA levels. This neuro-
protective effect of vitamin C observed here is consistent
with results from previous studies [40,41].
In the kidneys, cisplatin increased both IL-6 and TNF-
alpha mRNAs in all pretreatment groups relative to the
control/saline group (Figure 4B). Increases in kidney IL-
6 protein levels have been reported following cisplatin
treatment in an acute renal failure model [36]. Cisplatin-
induced increases in TNF-α protein expression has also
been observed in vitro [37,38] or following acute admin-
istration of cisplatin in mice (30 mg/kg i.p., [42]: 15 mg/
kg i.p., [43]). However, 60 days after the last of six cis-
platin treatments, IL-6, TNF-α, IL-1β and IL-10 mRNA
levels in the kidneys are similar in all treatment groups.
Albumin-thioredoxin [43] or rhodobacter sphaeroides
(Lycogen) in mice treated acutely with cisplatin [42] also
blunts the elevation of IL-6 and TNF-α mRNA levels inthe kidney. More work is necessary to show that inhib-
ition of IL-6 and TNF-α mRNA levels in the kidney by
antioxidants mediates renal protective effects following
repeated cisplatin injections and long term nephropro-
tective effects. Indeed, to our knowledge, the present
study is the first to evaluate the long term beneficial ef-
fects (60 days after the last of six cisplatin treatments) of
antioxidant pretreatments (with vitamin C) on body weight,
body temperature, kidney functions and interleukins in
mice receiving repeated cycles of cisplatin (once a week
5 mg/kg i.p. for 6 weeks).
Conclusions
Our studies provide direct evidence that once weekly
subcutaneous injections of either sodium bicarbonate
(NaHCO3) or vitamin C have a beneficial impact on ani-
mal health status and kidney function (normal creatinine
levels, normal kidney weight ratio and absence of mor-
tality) following repeated cisplatin treatment. Because
development of chemotherapy-induced neuropathy is
not altered by anti-oxidant treatments, our methods
permit long term assessments of cisplatin-induced
neuropathy (i.e. at least 60 days following the last of six
once weekly cisplatin injections across 96 days) that are
not confounded by unacceptable toxicity or impairment in
animal health. Furthermore, a full reversal of cisplatin-
induced mechanical and cold allodynia was produced by
either morphine or ibuprofen treatment and efficacy did
not differ as a function of the various pretreatment condi-
tions (i.e. sodium bicarbonate, vitamin C, resveratrol or sa-
line). By contrast, both saline or resveratrol pretreatments
prior to cisplatin negatively impacted renal function.
Moreover, IL-1β mRNA levels are increased in the lumbar
spinal cord of saline, NaHCO3 and resveratrol/cisplatin-
treated groups whereas IL-6 and TNF-alpha mRNAs are
elevated in the kidneys in all cisplatin-treated groups, but
normalized by 60 days after the last cisplatin treatment.
Thus, administration of sodium bicarbonate or vitamin C
prior to cisplatin treatment has long lasting beneficial ef-
fects on general health of rodents. The present approach
employing antioxidant treatment should permit compre-
hensive study of the different mechanisms underlying
cisplatin-induced neuropathy and facilitate identification
of effective prophylactic treatments.
Methods
Subjects
Male C57BL/J mice (Jackson labs, Bar Harbor, ME, USA)
weighing 26–33 g before testing, were used. Animals were
single housed in standard plastic cages with sawdust bed-
ding in a climate-controlled room, under a 12 h light/dark
cycle. The mice received free access to standard rodent
chow and water. All experimental research protocols was
carried out in accordance with the National Institute of
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imals and protocols approved by the Bloomington Indiana
University Institutional Animal Care and Use Committee
and all procedures conformed to the guidelines for the
treatment of animals established by the International As-
sociation for the Study of Pain [44].
Drugs
Morphine sulfate and ibuprofen sodium salt were pur-
chased from Sigma-Aldrich (St-Louis, MO, USA). Vitamin
C (acid ascorbic), sodium bicarbonate (NaHCO3) and cis-
platin were purchased from Tocris (Ellisville, MO, USA).
Resveratrol was provided by InvivoGen (San Diego, CA,
USA). Doses of morphine and ibuprofen were selected
based upon efficacy demonstrated in previous studies
[28,45,46]. Resveratrol was dissolved in 10% dimethylsulf-
oxide (DMSO) [20]. Vitamin C, sodium bicarbonate
(NaHCO3), morphine and ibuprofen were dissolved in
normal saline (0.9% NaCl in water) [22,28,46].
Protocol
First, we measured body weight and body temperature
of saline- (n = 18) or cisplatin-treated mice that were
pretreated with either: saline, vitamin C, resveratrol or
NaHCO3 (n = 9-11 per group). Using the same cohorts
of mice, we evaluated the effects of saline- or cisplatin-
treatments on mechanical paw withdrawal threshold
(electro von Frey stimulation) and latency of paw with-
drawal to acetone (cold responsiveness). A subset of
these animals was used to evaluate kidney functions
(creatinine levels in whole blood, urine and blood pH
and kidney weight ratio) as well as quantification of
mRNA levels of interleukins (IL-1β, IL-6, IL-10 and
TNFα) in spinal cord and kidneys. Another cohort of
mice was used to evaluate the anti-allodynic effects of
morphine and ibuprofen on cisplatin-induced mechanical
and cold allodynia in the different pretreatment (saline,
vitamin C, resveratrol or NaHCO3) groups. Subsequent
groups of mice treated with saline, saline/cisplatin and
vitamin C/cisplatin were evaluated to establish the long
term effects (60 days following termination of cisplatin
dosing) of the last cisplatin weekly administration on body
weight, body temperature, kidney functions, sensitivity to
mechanical and cold stimulation as well as mRNA expres-
sion levels of pro-inflammatory cytokines (IL-1β, IL-6,
IL-10 and TNFα) in spinal cord and kidneys.
Temperature measurement
Rectal temperature was assessed in animals receiving
different pretreatments (saline, bicarbonate (NaHCO3),
vitamin C and resveratrol) using a rectal probe (Physi-
temp RET-2 rectal probe for rats, Clifton, NJ, USA) and
meter (Physitemp Model BAT-12R, Clifton, NJ, USA).
Cisplatin has previously been shown to induce aberrantchanges such as lowered body temperature [6,8,29]. Body
temperature was recorded every four days from day 0 to
day 36. The same animals were used to evaluate body
weight and body temperature as well as mechanical and
cold allodynia. A subset (n = 8 per group) of these animals
was used to evaluate kidney functions. For the long term
study (60 days post termination of cisplatin dosing), an-
other cohort of mice was used to measure and evaluate:
body temperature, body weight, mechanical and cold
allodynia.
Development of neuropathic pain
Cisplatin (Tocris, Ellisville, MO, USA) was administered
intraperitoneally (i.p.) once a week at a dose of 5 mg/kg
for 6 (36 days) weeks (cumulative dose: 30 mg/kg i.p.)
[5]. Cisplatin was diluted in normal saline (0.9% NaCl)
and delivered in a volume of 10 ml/kg body weight.
Control groups were injected with an equivalent volume
of saline (i.p.) in lieu of cisplatin [8]. Before each cisplatin/
saline i.p. injection either (1) 0.9% NaCl [15]; (2) 4% so-
dium bicarbonate (NaHCO3 dissolved in 0.9% NaCl) [8];
(3) vitamin C (25 mg/kg s.c.) [22]; or (4) resveratrol
(25 mg/kg s.c.) [20] was administered subcutaneously in a
final volume of 1 ml. Injections were always performed
after completion of mechanical and cold withdrawal
testing.
Assessment of mechanical allodynia
Mechanical withdrawal thresholds were assessed using a
digital Electrovonfrey Anesthesiometer (IITC Life Sciences,
Woodland Hills, CA) equipped with a semi-flexible tip
[28,47]. The digital Electrovonfrey was used so the weight
is constantly displayed. Mice were placed in individual
plastic cages on an elevated wire mesh platform, and were
allowed to habituate to the testing apparatus for at least
30 minutes until exploratory behavior was no longer ob-
served. Force was applied to the midplantar region of each
hindpaw in each study by a single experimenter. Stable
baseline responses were obtained prior to experimental
testing. Mechanical stimulation was terminated upon paw
withdrawal; consequently, there was no upper threshold
limit set for termination of a trial. Paw withdrawal thresh-
olds were assessed in duplicate in each paw. Mechanical
withdrawal thresholds were measured every 4 days over
36 days. Testing took place on days 0, 4, 8, 12, 16, 20, 24,
28, 32 and 36 for all animals. For the long term study
(60 days post-cisplatin treatment), mice in relevant co-
horts were also tested every 4 days from day 36 to 96.
Assessment of cold allodynia
Cold allodynia was measured by applying drops of acet-
one to the plantar surface of the hind paw as previously
described [47,48]. Mice were placed in individual plastic
cages on an elevated platform and were habituated for at
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was loaded into a one ml syringe barrel with no needle
tip. Air bubbles were cleared from the syringe prior to
acetone application. One drop of acetone (approximately
20 μl) was applied through the mesh platform onto the
plantar surface of the hind paw. Care was taken to gently
apply the bubble of acetone to the skin on the paw with-
out inducing mechanical stimulation through contact of
the syringe barrel with the paw. Paw withdrawal time in
a 60 s observation period after acetone application was
recorded. Paw withdrawal was sometimes associated with
a secondary response with the animal, such as rapid flick-
ing of the paw, chattering, biting, and/or licking of the
paw. Testing order alternated between paws (i.e. right and
left) until five measurements were taken for each paw. An
interstimulation interval of approximately 5 minutes was
allowed between testing of right and left paws. Cold allo-
dynia testing took place on days 0, 4, 8, 12, 16, 20, 24, 28,
32 and 36 for all animals. For the long term study (60 days
post-cisplatin treatment), the mice were also tested every
4 days from day 36 to 96.
Assessment of kidney functions
Creatinine, ketone and glucose levels (mg/dL) were mea-
sured in whole blood using the PTS CardioChek diag-
nostic apparatus (Cliawaived.com, San Diego, CA, USA).
Urine and blood were extracted post mortem [8]. Urine
and blood pH was measured using a digital pH 110 m
(Oakton Instruments, Vermon Hills, IL, USA). The kidney
to body weight ratio was also measured [20].
Sample preparation for RT-PCR analysis
Animals receiving control/saline (n = 4), saline/cisplatin
(n = 4), sodium bicarbonate (NaHCO3)/cisplatin (n = 4),
vitamin C/cisplatin (n = 4) and resveratrol (n = 4) (see
methods) were killed by rapid decapitation without
anesthesia at day 36 following initiation of cisplatin
dosing to generate spinal cord and kidney samples used
for mRNA quantification. Separate cohorts of mice treated
with control/saline (n = 4), saline/cisplatin (n = 4) and vita-
min C/cisplatin (n = 4) were killed by rapid decapitation
without anesthesia at day 96 (60 days following termin-
ation of cisplatin dosing) to generate spinal cord and kid-
ney samples used in mRNA quantification. Lumbar spinal
cord and both kidneys were rapidly fast frozen in isopen-
tane precooled on dry ice (−30°C) and stored at −80°C
until use as described previously [28].
Quantification of spinal cord and kidney mRNA
Real time RT-PCR was used to quantify mRNA levels as
previously described [28]. RNA from spinal cord and
kidneys of mice treated with control/saline, saline/cis-
platin, NaHCO3/cisplatin, vitamin C/cisplatin and resvera-
trol/cisplatin were extracted using a TRIzol (Ambion, CA,USA)/RNeasy (Qiagen, CA, USA) hybrid protocol accord-
ing to manufacturer’s instructions. Purified RNA from
each sample was then treated with DNase 1(New England
BioLabs, MA, USA). Expression levels of IL-1β, IL-6,
IL-10 and TNFα mRNAs were quantified using one step
RT-PCR with PowerSYBR green PCR kit (Applied Biosys-
tems, Carlsbad, CA,USA) by a Matercycler ep realplex RT-
PCR machine (Eppendorf Norh America Inc., Hauppauge,
NY,USA). GAPDH (glyceraldehyde-3-phosphate dehydro-
genase) was used as internal standard to normalize mRNA
levels. Primers used were as follows: mouse GAPDH (sense:
5′-GGGAAGCTCACTGGCATGGC-3′, anti-sense: 5′- G
GTCCACCACCCTGTTGCT-3′); mouse IL-1β (sense:
5′-CGTGGACCTTCCAGGATGAG-3′, anti-sense: 5′-C
ATCTCGGAGCCTGTAGTGC-3′); mouse IL-6 (sense:
5′-GCCTTCTTGGGACTGATGCT-3′, anti-sense: 5′-TG
CCATTGCACAACTCTTTTC-3′); mouse IL-10 (sense:
5′-GGCGCTGTCATCGATTTCTC-3′, anti-sense: 5′-GG
CCTTGTAGACACCTTGGTC-3′); mouse TNFα (sense:
5′-CGTCGTAGCAAACCACCAAG-3′, anti-sense: 5′-TA
GCAAATCGGCTGACGGTG-3′).Statistical analysis
All experiments were conducted in a blinded manner.
Animals were randomly assigned to experimental condi-
tions. Paw withdrawal thresholds (mechanical) and laten-
cies (cold) were calculated for each paw and averaged.
Data were analyzed using analysis of variance (ANOVA)
for repeated measures or one-way ANOVA as appropriate.
The Greenhouse-Geisser correction was applied to all re-
peated factors; degrees of freedom reported for significant
interactions are the uncorrected values. The source of sig-
nificant interactions was further evaluated by performing
one way ANOVAs at each individual time point, followed
by Bonferroni post hoc tests. The different components of
the total variation were settled a priori using multiple re-
gression analysis [49]. Analyses were performed using
SPSS statistical software (version 21.0; SPSS Incorporated,
Chicago, IL, USA). P < 0.05 was considered significant.
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